Clinigen Group (CLIGF) Rating Increased to Hold at Zacks Investment Research

Share on StockTwits

Clinigen Group (OTCMKTS:CLIGF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of OTCMKTS CLIGF remained flat at $$9.87 on Tuesday. Clinigen Group has a 12-month low of $9.87 and a 12-month high of $12.59.

Featured Story: Roth IRA

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.